Investing
Argus Makes Model Portfolio Changes (NUE, HCP, MDT, AMGN, HUM, ADI, JNPR, ELX, IPG)
Published:
Argus offers what is truly considered to be independent investment research. This gives the firm the lack of any or most of the traditional conflicts of interest that can be the case as far as Wall St. sell-side upgrades and downgrades are concerned. That is perhaps one of the top reasons why we give them high marks when their team of CFAs and analysts come up with research ideas.
In the Equity Income model portfolio, the firm says to add to positions in Nucor Corp. (NYSE: NUE) and in HCP Inc. (NYSE: HCP).
In the Growth & Income model portfolio, Argus said to buy Medtronic Inc. (NYSE: MDT) and Amgen Inc. (NASDAQ: AMGN). It also said to sell its positions in Humana Inc. (NYSE: HUM) and in Analog Devices Inc. (NASDAQ: ADI).
The final model portfolio changes came in the Mid-Cap Growth portfolio. Argus recommended buying a full position in Juniper Networks Inc. (NYSE: JNPR) at $17.82 and selling the full position in Emulex Corp. (NYSE: ELX), as well as selling out the position in Interpublic Group of Companies Inc. (NYSE: IPG).
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.